Format

Send to

Choose Destination
Autoimmun Rev. 2013 Jul;12(9):885-93. doi: 10.1016/j.autrev.2013.03.011. Epub 2013 Mar 26.

Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis.

Author information

1
Unité Mixte de Recherche-CNRS UMR7215/INSERM U974/UPMC UM76/AIM-Thérapie des Maladies du Muscle Strié, Groupe Hospitalier Pitié-Salpêtrière, 105 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France. sonia.berrih-aknin@upmc.fr

Abstract

Myasthenia gravis (MG) is an autoimmune disease mediated by antibodies directed to molecules of the endplate of the neuromuscular junction. B cells play a major role in MG disease since they produce the pathogenic antibodies and therapies targeting B cells are effective. The aim of this article was to review the role of B cells in myasthenia gravis. We will first describe what we know about B cells in this disease and examine the involvement of the B cells in the thymus of MG patients. We will detail the role of factors associated with B-cell function such as BAFF. Finally, we will discuss the effects of therapy targeting B cells.

PMID:
23537509
DOI:
10.1016/j.autrev.2013.03.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center